Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for Levocap ER
Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has entered into an agreement with Memorial Sloan Kettering Cancer Center (MSKCC) in a series of animal studies for levorphanol, the active ingredient of LevoCap ER, a new tamper-resistant, extended release form of levorphanol. Gavril Pasternak, MD, PhD, of MSKCC is the lead investigator for these studies.
View full press release